Apogee Therapeutics (NASDAQ:APGE) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Posted by Brenda Bartman on Aug 10th, 2026

Apogee Therapeutics (NASDAQ:APGE – Get Free Report) issued its earnings results on Monday. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.07), FiscalAI reports.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $134.84 on Monday. Apogee Therapeutics has a fifty-two week low of $34.34 and a fifty-two week high of $134.88. The stock’s 50 day simple moving average is $119.35 and its two-hundred day simple moving average is $91.96. The stock has a market cap of $8.34 billion, a price-to-earnings ratio of -31.14 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Stifel Nicolaus reissued a “hold” rating and set a $135.00 price target (up from $133.00) on shares of Apogee Therapeutics in a research report on Wednesday, June 24th. Rothschild & Co Redburn initiated coverage on shares of Apogee Therapeutics in a research report on Friday, May 1st. They issued a “buy” rating and a $140.00 price objective on the stock. UBS Group lowered shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and increased their target price for the stock from $100.00 to $135.11 in a report on Tuesday, June 23rd. BTIG Research reissued a “buy” rating and issued a $137.00 target price on shares of Apogee Therapeutics in a research note on Wednesday, May 27th. Finally, The Goldman Sachs Group set a $89.00 price target on Apogee Therapeutics in a research report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $121.25.

Read Our Latest Report on Apogee Therapeutics

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total transaction of $3,500,640.00. Following the sale, the insider directly owned 179,248 shares in the company, valued at $23,768,284.80. The trade was a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the completion of the sale, the chief executive officer directly owned 1,015,987 shares in the company, valued at approximately $134,658,916.98. The trade was a 7.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 182,900 shares of company stock valued at $21,986,750. 24.30% of the stock is currently owned by company insiders.

Institutional Trading of Apogee Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC purchased a new position in Apogee Therapeutics during the 4th quarter valued at about $37,000. Ensign Peak Advisors Inc bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at approximately $170,000. Quantbot Technologies LP bought a new position in shares of Apogee Therapeutics during the third quarter valued at approximately $96,000. Quarry LP purchased a new position in shares of Apogee Therapeutics during the fourth quarter valued at approximately $189,000. Finally, Vident Advisory LLC bought a new stake in shares of Apogee Therapeutics in the 4th quarter worth approximately $218,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

About Apogee Therapeutics

(Get Free Report)

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.